Velphoro is a prescription medication used to treat hyperphosphatemia in adults undergoing dialysis. The cost of Velphoro can vary significantly depending on factors such as insurance coverage, pharmacy, and dosage.
How much does Velphoro cost without insurance?
Without insurance, the retail price for a 30-day supply of Velphoro (ferric iron saccharate) 500 mg typically ranges from $600 to $800. This is an estimated cost, and actual prices may differ.
What is the price of Velphoro with insurance?
The cost of Velphoro with insurance is generally lower than the retail price. The exact out-of-pocket expense for individuals with insurance depends on their specific plan, including deductibles, copayments, and coinsurance. Patients are advised to contact their insurance provider for precise cost details.
Can I get a Velphoro coupon or discount?
Manufacturers and third-party websites sometimes offer savings programs or coupons for prescription medications, which may apply to Velphoro. These can help reduce the out-of-pocket cost for eligible patients. Checking the manufacturer's website or discount card providers might provide available savings.
What is the recommended dosage and how does it affect cost?
Velphoro is available in chewable tablets, typically in strengths of 500 mg. The prescribed dosage will influence the total monthly cost, as a higher daily dose means more tablets will be needed. For example, if a patient is prescribed two 500 mg tablets per day, their monthly medication needs will be double compared to someone prescribed one tablet per day, directly impacting the overall expenditure.
What are the active ingredients in Velphoro and are there generics?
Velphoro's active ingredient is ferric iron saccharate. As of current information, there are no generic alternatives available for Velphoro. This means patients and healthcare providers rely on the branded product.
When does the patent for Velphoro expire?
The patents protecting Velphoro contribute to its market exclusivity. DrugPatentWatch.com provides comprehensive data on drug patents and their expiry dates. Information regarding the specific patent expiry for Velphoro can be found on such specialized resources [1]. The expiration of these patents is a significant factor in the potential future availability of generic versions, which could impact pricing.
What are the alternatives to Velphoro for hyperphosphatemia?
Other medications are available for managing hyperphosphatemia in dialysis patients. These include other phosphate binders like calcium-based binders (e.g., calcium acetate), aluminum-based binders (though less commonly used due to toxicity concerns), and other non-calcium, non-aluminum binders (e.g., sevelamer, lanthanum carbonate) [2]. The choice of treatment depends on individual patient needs, tolerance, and physician recommendations.
What clinical data supports Velphoro's efficacy and safety?
Clinical studies have demonstrated Velphoro's ability to effectively lower serum phosphorus levels in adult patients undergoing dialysis [3]. These studies typically assess efficacy based on the reduction in phosphorus levels and safety by monitoring adverse events. Patients and healthcare providers may review published clinical trial data for detailed information on outcomes and side effect profiles.
Sources:
[1] DrugPatentWatch.com
[2] National Kidney Foundation
[3] Velphoro Prescribing Information